Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial (UMA)

This study has been withdrawn prior to enrollment.
(faillure to obtain insurance because of refusal from insurance companies)
Sponsor:
Collaborators:
Gilead Sciences
Merck Sharp & Dohme Corp.
GlaxoSmithKline
Abbott
Information provided by (Responsible Party):
French National Agency for Research on AIDS and Viral Hepatitis
ClinicalTrials.gov Identifier:
NCT00936195
First received: July 8, 2009
Last updated: February 14, 2012
Last verified: February 2012

July 8, 2009
February 14, 2012
January 2010
January 2013   (final data collection date for primary outcome measure)
cumulative occurence of : -adverse pregnancy outcomes (spontaneous abortion, stillbirth, congenital abnormality requiring surgical correction in children < 1 yr of age); -paediatric HIV infection; -infant mortality [ Time Frame: at 6 and 12 months following delivery/birth ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00936195 on ClinicalTrials.gov Archive Site
  • occurence of grade 4 events in treated women, and of grade 3 or 4 events in ARV-exposed infants [ Time Frame: at 6 and 12 months following delivery/birth ] [ Designated as safety issue: Yes ]
  • frequency of virological failure (>300 copies/mL) and viral resistance profile [ Time Frame: at 6 month and 12 months post-delivery ] [ Designated as safety issue: No ]
  • frequency of premature delivery (<37 weeks) and frequency of low birth weight (<2500 g) [ Time Frame: at delivery/birth ] [ Designated as safety issue: Yes ]
  • cumulative incidence of paediatric HIV infection [ Time Frame: at 12 months after delivery ] [ Designated as safety issue: No ]
  • tolerability of the ARV combination in treated women [ Time Frame: at 6 and 12 months following delivery/birth ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial
Safety and Efficacy of the Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations in Pregnant and Breastfeeding Women to Prevent mother-to Child Transmission of HIV-1 o, Resource-limited Settings: A Multicentre Randomized Phase 3 Clinical Trial

To assess the maternal and infant safety of a single daily fixed-dose combination of TDF/FTC/EFV (Atripla®), compared to the association of LPV/r (Kaletra® or Aluvia®) and 3TC/ZDV (Combivir®) given to African women to prevent overall MTCT in populations practicing breastfeeding.

The prevention of MTCT during pregnancy and through breastfeeding exposure remains challenging to date in most resource-limited settings. Peripartum HIV transmission is already amenable to ARV interventions. These ARV regimens, partially efficacious are insufficiently used despite their apparent simplicity. The postnatal transmission via breastfeeding remains a serious additional threat.

This is a multicentric, non-inferiority, randomized controlled trial aiming at assessing the maternal and infant safety of a single daily fixed-dose combination of TDF/FTC/EFV (Atripla®), compared to the association of LPV/r (Kaletra® or Aluvia®) and 3TC/ZDV (Combivir®) given to African women (in Cote d'Ivoire an in Zambia) to prevent MTCT overall in breastfeeding population.

The fixed-dose combination of Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV or Atripla®) is a highly effective HAART combination and the simplest ARV regimen currently available in resource-limited settings and is therefore likely to become soon the lead first-line HAART regimen for adults in such settings. Its anticipated widespread prescription in women of childbearing age requires the proper documentation of its use in pregnancy and during breastfeeding.

The combination of ZDV/3TC (Combivir®) and Lopinavir/ritonavir (LPV/r) (Kaletra® or Aluvia®) is chosen as a reference regimen as it is one of the most commonly used first-line HAART for adults and the reference regimen for PMTCT in industrialised settings.

The maternal ARV regimen will be initiated as soon as possible from 20 weeks of gestation until at least the cessation of breastfeeding (with the advice to cease at six months). The decision to stop or continue the maternal ARV regimen after breastfeeding cessation will be based on the baseline maternal CD4 count and the maternal clinical stage at baseline and/or at breastfeeding cessation. A woman with a baseline CD4 <500 cells/ml will always be proposed to continue her treatment after breastfeeding cessation. A woman with a baseline CD4 count >500 will be asked to stop her treatment after breastfeeding cessation unless she has reached the WHO clinical stage IV at that time.

Infants will receive daily Zidovudine syrup from birth during the first week of life, or an updated ARV post-exposure prophylaxis recommended by WHO when women receive HAART.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • HIV Infection
  • Pregnancy
  • Breastfeeding
  • HIV Infections
  • Drug: Efavirenz-Tenofovir-Emtricitabine
    Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
  • Drug: Zidovudine-Lamivudine-Lopinavir/Ritonavir

    Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day

    Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day

  • Active Comparator: Atripla (R)
    Intervention: Drug: Efavirenz-Tenofovir-Emtricitabine
  • Active Comparator: Combivir (R) + Kaletra (R) or Aluvia (R)
    Intervention: Drug: Zidovudine-Lamivudine-Lopinavir/Ritonavir
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
June 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • being pregnant, presenting in at least the 20th week of pregnancy and no later than 2 weeks before the expected term;
  • at least 18 years of age;
  • diagnosed as infected with HIV-1 only;
  • not currently taking any ARV drugs;
  • having not been exposed to NVP in the 6 months preceding enrolment;
  • willing to breastfeed their forthcoming child;
  • residing and planning to continue to reside within the predefined catchment areas until 12 months after delivery;
  • being able to give informed consent for enrolment in the study;
  • lacking any medical contraindication to any of the proposed ARV medications;
  • and accepting the principle of being randomized to receive one of the ARV regimens evaluated within the study, to prevent MTCT and for their own health when required.

Exclusion Criteria:

  • presenting within 2 weeks before the expected term;
  • currently taking ARV drugs;
  • having been exposed to NVP in the 6 months preceding enrolment;
  • not willing to breastfeed their forthcoming child;
  • having severe renal insufficiency (creatin clearance < 60ml/min);
  • diagnosed as infected with HIV-2 only or dually infected HIV-1 and HIV-2;
  • hemoglobin < 7 g/dL in the month preceding inclusion
  • HBs Ag positive

Women meeting one of the three last exclusion criteria (HIV-2 infection or co-infection, hemoglobin < 7 g/dL, HBs Ag positive) will not be randomized but will all received Atripla and be followed-up in an ancillary open cohort according the same procedures and agenda.

Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Côte D'Ivoire,   Zambia
 
NCT00936195
ANRS 12200 UMA
Yes
French National Agency for Research on AIDS and Viral Hepatitis
French National Agency for Research on AIDS and Viral Hepatitis
  • Gilead Sciences
  • Merck Sharp & Dohme Corp.
  • GlaxoSmithKline
  • Abbott
Study Chair: Didier K Ekouevi, MD, PhD Programme PACCI Abidjan, Cote d'Ivoire
Study Chair: François Dabis, MD, PhD Bordeaux 2 University, France
French National Agency for Research on AIDS and Viral Hepatitis
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP